We discovered that pigment epithelium-derived factor (PEDF)-null mice have endometrial hyperplasia, the precursor to human type I endometrial cancer (ECA), which is etiologically linked to unopposed estrogen (E2), suggesting that this potent antiangiogenic factor might contribute to dysregulated growth and the development of type I ECA. Treatment of both ECA cell lines and primary ECA cells with recombinant PEDF dose dependently decreased cellular proliferation via an autocrine mechanism by blocking cells in G 1 and G 2 phases of the cell cycle. Consistent with the known opposing effects of E2 and progesterone (Pg) on endometrial proliferation, Pg increases PEDF protein synthesis and release, whereas E2 has the converse effect. Using PEDF luciferase promoter constructs containing two Pg and one E2 response elements, E2 reduced and Pg increased promoter activity due to distal response elements. Furthermore, E2 decreases and Pg increases PEDF secretion into conditioned media (CM) by both normal endometrial stromal fibroblasts (ESFs) and cancer-associated fibroblasts (CAFs), but only CM from ESFs mediated growth-inhibitory activity of primary endometrial epithelial cells (EECs). In addition, in cocultures with primary EECs, Pg-induced growth inhibition is mediated by ESFs, but not CAFs. This is consistent with reduced levels of Pg receptors on CAFs surrounding human malignant glands in vivo. Taken together, the data suggest that PEDF is a hormone-regulated negative autocrine mediator of endometrial proliferation, and that paracrine growth inhibition by soluble factors, possibly PEDF, released by ESFs in response to Pg, but not CAFs, exemplifies a tumor microenvironment that contributes to the pathogenesis of ECA.
ndometrial cancer (ECA) is the most common gynecological cancer, occurring at a rate of 54,870 in 2015 in the United States (1) . The most common clinical, endocrine, and epidemiological subtypes are divided into type I and II ECA (2) . According to the Bokhman (International Federation of Gynecology and Obstetrics) classification, type I ECA is histologically endometrioid and occurs at a rate of 60% to 70%, and type II ECA has serous papillary histology, is more aggressive, and occurs in ;30% of cases (3, 4) . Ovarian estrogens (E2) and progesterone (Pg), derived from the corpus luteum following ovulation, regulate growth of the endometrial glandular epithelium in a cyclical manner. E2 is mitogenic during the proliferative phase of the menstrual cycle, whereas Pg suppresses E2-induced action, promoting differentiation of endometrial glands in the secretory phase. Unopposed E2, as is the case in anovulation and menopause, can lead to endometrial hyperplasia, a precursor to type I carcinoma. In contrast, synthetic progestins are successful therapeutics for complex atypical hyperplasia (AEH) and low-grade type I ECA (5) (6) (7) (8) . Therefore, a deeper understanding of mechanisms involved in steroid hormone-regulated growth of endometrial glands should further elucidate potential molecular targets for type I ECA therapeutics.
Pigment epithelium-derived factor (PEDF), a 50-kDa secreted acidic glycoprotein, is structurally related to the serine protease inhibitor (serpin) superfamily, but does not possess this function (9) . PEDF was first identified as a neurotrophic factor in the conditioned media (CM) of human fetal retinal pigment epithelial cells (10) . As PEDF has been identified as the most potent endogenous antiangiogenic factor, its presence in the mammalian eye is critical for preventing vessel growth in the lens causing blindness (11) (12) (13) . In addition to its antiangiogenic effect on intratumoral vasculature, PEDF has direct effects on tumor cells and, therefore, is touted as a potential molecular therapeutic target for cancer (14, 15) . Decreased levels of PEDF expression have been shown in a variety of cancers, including glioma, mesothelioma, melanoma, and cancers of the prostate, lung, ovary, and pancreas (14, (16) (17) (18) (19) , and PEDF can directly induce differentiation of tumors to a less malignant phenotype (20) . In an orthotopic model of osteosarcoma, PEDF treatment decreased tumor size and metastasis and, in vitro, inhibited proliferation of the human osteosarcoma cell line, SaOS-2 (21, 22) . Exogenous PEDF inhibits the growth and induces apoptosis of a variety of cancer cell lines in vitro, including prostate cancer cells and tumor xenografts (14, 23, 24) , and varied anti-cancer effects of Metformin on prostate cancer cells in vitro and in vivo were attributed to the upregulation of PEDF (25) . Whereas PEDF induces survival of many normal cell types of neural origin, it increases apoptosis of cancer cell types through activation of both the extrinsic and intrinsic pathways (26) , and, furthermore, other anti-cancer effects include decreasing cancer cell migration and invasion by notably downregulating matrix metalloproteinases (27) . PEDF ligand-induced functions are attributed to signaling by different membrane receptors such as ATGL, a lipase-linked PEDF receptor (PEDFR) responsible for certain anti-cancer actions (14) ; F1ATP synthase (28) ; the WNT coreceptor, LRP6 (29) ; and the laminin receptor, which is linked to PEDF antiangiogenic activity of endothelial cells (30) .
Angiogenesis is an important function in the endometrium, and, consistent with the role of E2 in forming and increasing the uterine lining, antiangiogenic PEDF has been shown to be decreased by E2 in the proliferative phase of the menstrual cycle (31) . Conversely, Pg increases PEDF and, thus, is shown to be highly expressed in endometrial epithelial cells (EECs) likely for inhibition of growth and induction of differentiation in late secretory phase endometrium. Therapeutic effects of PEDF have been implicated for a variety of uterine pathologies, as suggested by a rat model of endometriosis (32) and in Tamoxifen-induced vascular endothelial growth factor (VEGF), associated with endometrial hyperplasia (33) .
As shown in this work, at birth, 100% of PEDF-null mice demonstrate striking endometrial hyperplasia associated with increased proliferation and neovascularization. As endometrial hyperplasia occurs concurrently and precedes E2-linked human type I ECA (34) , the results suggested that loss of PEDF expression might be involved in the pathogenesis of ECA. We show that exogenous recombinant PEDF inhibits proliferation of ECA cell lines and primary ECA cells. In addition, PEDF is released by ECA cells that control growth in an autocrine manner. Consistent with the opposing effects of E2 and Pg on endometrial cell growth, E2 decreased and Pg increased the messenger RNA (mRNA), protein, and secretion of PEDF in primary EECs and ECA cells and ECA cell lines. Through cell:cell interactions and release of factors, endometrial stromal fibroblasts (ESFs) that surround epithelial glandular cells in hormone-regulated organs regulate the growth and differentiation of adjacent EECs (35) (36) (37) (38) . Our data show that CM from normal ESFs, but not cancerassociated fibroblasts (CAFs), has paracrine growthinhibitory activity on target primary EECs. Furthermore, in cocultures, addition of Pg inhibited proliferation of normal primary EECs in the presence of ESFs, but stimulated EEC proliferation when in cocultures with CAFs. Although the levels of PEDF secreted by individual patients' ESFs did not correlate with inhibition of proliferation of EECs, the levels of PEDF secreted by ESFs in vitro are within the level shown to inhibit the growth of primary ECA cells and ECA cell lines, and, thus, we propose that PEDF could have growth-inhibitory activity locally, in vivo. Finally, the level of expression of PEDF in ECA tissues was not lower in ECA. Therefore, whereas PEDF appears to be important to growth inhibition of the endometrium in vivo in mice, inhibits proliferation of human ECA cells, and is responsive to hormonal regulation in normal and malignant-derived endometrial epithelial and stromal cells, the loss of PEDF expression in ECA was not demonstrated in the cohort of patients evaluated in this study. However, a subset of ECA patients, such as higher grade tumors, may have reduced PEDF with functional consequences. Alternatively, overexpression of PEDF may signify loss of negative feedback control due to aberrant PEDF signaling.
Materials and Methods

Cell culture and steroid hormone treatments
The endometrial carcinoma (ECA) cell lines HEC-1A and HEC-1B (moderately differentiated adenocarcinoma), KLE (poorly differentiated adenocarcinoma), RL-95-2 (moderately differentiated adenosquamous carcinoma), and ECC-1 (welldifferentiated adenocarcinoma) were purchased from American Type Culture Collection (Manassas, VA). All cell lines were authenticated by short terminal repeat profiling (DDC Medical, Fairfield, OH). The cells were seeded, maintained, and passaged according to American Type Culture Collection guidelines: HEC-1A in McCoy 5A with 10% fetal bovine serum (FBS); HEC-1B in minimal essential media (Life Technologies, Camarillo, CA) with 10% FBS (Hyclone, Logan, UH), nonessential amino acids, and 1 mM sodium pyruvate (Life Technologies); and KLE, ECC-1, and RL-95-2 in Dulbecco's modified Eagle medium (DMEM)/F12 (Life Technologies) with 10% FBS. Primary EECs, carcinoma (ECA) cells, and stromal cells were isolated from fresh hysterectomy tissue procured from New York University Langone Medical Center and Bellevue Hospitals, as previously described (39) . Primary EECs were seeded onto 6.0 cm Primaria tissue culture plates (BD Falcon, San Jose, CA) at a density of 4 to 6 3 10 6 in McCoy 5A supplemented with 10% charcoal-stripped FBS (Hyclone). Stromal fibroblasts isolated from normal endometrium (ESFs) and CAFs from malignant endometrium were cultured in DMEM/F-12 with 10% FBS containing antibioticantimycotic (100 U/mL penicillin, 100 mg/mL streptomycin, and 0.25 mg/mL Fungizone; Invitrogen, Waltham, MA). In addition, the cells were directly plated into 96-well plates to determine the effect of PEDF on cell proliferation (described below). For steroid hormone treatments, the epithelial and stromal cells were seeded at 2.0 3 10 5 and 1.0 3 10 5 /well, respectively, in six-well plates and cultured to 60% to 70% confluence, synchronized in G 1 by serum starvation in 1% charcoal-stripped FBS for 24 hours, and subsequently treated with 17b-estradiol (E2, 1 nM; Sigma-Aldrich, St. Louis, MO) or medroxyprogesterone 17-acetate (MPA; 100 nM; Sigma-Aldrich) in the presence of 100 nM E2 for 48 hours. The concentrations of hormones used in this work were determined from previous dose-response studies (39, 40) . For specificity of the response through hormone receptor signaling, the E2 receptor antagonist, ICI 182,780 (10 nM; Astra Zeneca Limited, Cambridge, UK), and Pg receptor (PR) antagonist Mifepristone (10 mM; RU486; Sigma-Aldrich, St. Louis, MO) were used in experiments where shown.
PEDF-null mouse model
PEDF-deficient mice were generated by homologous recombination using a construct that replaced Serpinf1 exons 3 to 6 with a cassette containing an internal ribosomal entry site and the b-galactosidase and neomycin-resistance genes (Genome Systems). Embryonic stem cell DNA was digested with EcoR1 and was screened by Southern blotting. Mouse genomic DNA was genotyped using polymerase chain reaction (PCR) primers amplifying the wild-type (737-bp) and null (449-bp) alleles and compared with a positive control (1 mg C57Bl6/J DNA with 5.2 pg Serpinf1-null vector DNA) and a negative control (all reagents except DNA). Genotypes were confirmed on a second DNA sample obtained at the time of euthanasia. Briefly, the PEDF-null mice develop tumors, mainly of hematopoietic malignancies, and have features of metabolic syndrome and exhibit epithelial hyperplasia in many organ systems, including two hormone-sensitive organs, the uterus and the prostate (23) . Unlike age-matched and estrous cycle-matched control mice (n = 25), the epithelial hyperplastic changes can be detected in all PEDF-null female animals evaluated (n = 30; evaluated at 6, 12, and 18 months), and the phenotype is progressive with age; cancer of the uterus was not shown within the 18 months under observation. Animals were housed in accordance with guidelines set forth by the American Association for Laboratory Animal Care, and the research protocols were approved by the institution's Animal Care and Use Committee. Only female mice were used for this study requiring endometrial tissue.
Production of recombinant PEDF
Recombinant PEDF was prepared, as previously described (13) . Briefly, HEK cells were stably transfected with a pCEP4 construct (Invitrogen, Waltham, MA) containing the full-length PEDF complementary DNA and a C-terminal His-tag. Recombinant PEDF was purified from the CM of HEK-PEDF cells, grown under serum-free conditions, using ProBond nickel-chelating resins (Invitrogen) and a gradient of imidazole buffer elution, according to manufacturer's instructions. To evaluate purity, eluted protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and silver staining (Supplemental Fig. l ; Thermo Scientific, Waltham, MA). The eluate was concentrated using an Ultrafree protein centrifugal filter (10-kDa cutoff; Millipore, Billerica, MA), dialyzed against three changes of 0.1 M Tris buffer (pH 7.4) at 4°C, aliquoted, and stored at 220°C.
Immunohistochemical analysis for PEDF, proliferating cell nuclear antigen, microvessel density (CD31) in normal and PEDF-null mouse uterus and for PEDF and PR in human endometrial tissues
Mouse endometrial tissue fixed in 10% formalin, embedded in paraffin, were cut at 5 mm onto glass slides and immunostained for PEDF, the endothelial cell marker, CD31, and proliferating cell nuclear antigen (PCNA) to determine proliferating cells. The PEDF antibody was raised in rabbits to a peptide (amino acid residues 327 to 343) and purified on a peptide column, as described (41) , and immunohistochemistry (IHC) was performed, as described (23) . Briefly, the slides were deparaffinized and treated with 3.3% H 2 O 2 in methanol for 1 hour, followed by antigen retrieval in 10 mM citrate buffer with boiling for 15 minutes. Instructions and reagents from the Vectastain Elite avidin biotin complex (ABC) kit were used (PK-6100; Vector Laboratories, Burlingame, CA). Tissues were blocked with goat serum in phosphate-buffered saline (PBS) containing 0.1% bovine serum albumin for 30 minutes and incubated for 1 hour with the rabbit anti-PEDF antibody diluted at 1:50, mouse anti-PCNA (M0879; DAKO, Carpinteria, CA) antibody diluted at 1:200, and mouse anti-CD31 (SC-1506; Santa Cruz Biotechnology, Santa Cruz, CA) antibody diluted at 1:300, in blocking serum. Biotinylated goat anti-rabbit or antimouse secondary antibody was added to the slides for 30 minutes, followed by incubation for 30 minutes in ABC reagent, and finally, the slides were treated with 0.05% 3,3 0 -diaminobenzidine (SigmaAldrich) in 50 mM Tris containing 0.01% H 2 O 2 until brown color appeared. The slides were counterstained with Gills hematoxylin 3 (Fisher, Hampton, NH) and dehydrated, and coverslips were mounted. PCNA and microvessel density (MVD) were determined by counting all CD31-positive vessels or PCNApositive endometrial epithelial cells in 10 random high-power fields in a blinded fashion; the average for each mouse tissue is shown on the graphs 6 standard deviation (SD).
Archival paraffin-embedded human endometrial tissues of normal, hyperplastic, and ECA were obtained from New York University Tisch Hospital and Bellevue Tumor Registry. The tissues were previously graded according to the World Health Organization system. Normal tissues were obtained from noncancer-related hysterectomies. Full Internal Review Board approval was obtained from New York University School of Medicine (Assurance of Compliance number M1177-01). Paraffin-embedded tissues on slides (4.0 mm) were subjected to immunohistochemical analysis using rabbit anti-PEDF antibody (AB-PEDF1; BioProducts MD, Middletown, MD) diluted at 1:75 in blocking serum (Vectastain Elite ABC kit). The tissues on slides were processed essentially as described above for mouse IHC. The intensity of nuclear and cytoplasmic immunostaining for PEDF separately, in glandular epithelial and stromal cells in the categories of proliferative endometrium (PE), secretory endometrium (SE), simple hyperplasia (SH) without atypia, atypical complex hyperplasia (CH), and grades I, II, and III ECA, was assessed by three pathologists, and the predominant intensity level observed was scored on a scale of 0 to 4. The values obtained were multiplied by estimated percentage of cells staining at the assigned intensity score. Normal rabbit immunoglobulin G was used as a negative control (data not shown). The difference in immunostaining intensity between the epithelial and the stromal compartments was determined using a Wilcoxon matched-pairs signed rank test. The differences in PEDF values across each histological category were determined using the Kruskal-Wallis nonparametric test, followed by a Dunn test for multiple comparisons, using GraphPad Prism Software.
Many of the same patients' tissues were immunostained for PR. Peroxidase activity was blocked with 3% H 2 0 2 in methanol for 30 minutes, and antigen retrieval was performed using 10% Citra solution (BioGenex, Fremont, CA) in a microwave. Using the Vectastain Elite ABC kit, briefly, the tissues were blocked with nonimmune mouse serum in Tris-buffered saline/bovine serum albumin for 20 minutes and incubated overnight with antihuman PR monoclonal antiserum (1:50; NCL-PGR-312; Leica Microsystems, Wetzlar, Germany) at 4°C, and the slides were treated with anti-mouse secondary antibody, and then, by ABC reagent, followed by incubation in 3,3 0 -diaminobenzidine and counterstaining, as described above. The tissue sections were evaluated by light microscopy (Zeiss Photomicroscope II), and the intensity of immunostaining was scored 0 to 1, reflective of the number of nuclei staining in a visual field for the glands and stroma separately, for each tissue category PE, SE, CH, and grade I-III ECAs. A nonparametric Mann-Whitney test was used to compare PR scores. In all of the above, normal mouse or rabbit serum was used as a negative control.
Assays for cellular proliferation, cell cycle analysis, and apoptosis ECA cell lines were seeded at 5 3 10 3 cells/well onto 96-well culture plates (BD Falcon). The primary EECs and ECA cells were seeded at 3 3 10 4 cells/well in 96-well Primaria plates. Cells were cultured to 50% to 60% confluence, synchronized in G 1 by serum starvation in 1% FBS for 24 hours, and subsequently treated with increasing concentrations of recombinant PEDF in 1% FBS for 72 hours. To determine whether PEDF has an autocrine effect on cell proliferation, HEC-1B cells were seeded at the density described above in a 96-well plate, synchronized as above, and subsequently incubated with PEDF antibodies from three different manufacturers at 1 mg/mL (I-15, SC-16956, Santa Cruz Biotechnology; AB-PEDF1, Bioproducts MD; MAB1059, Millipore) for 72 hours. To knock down PEDF, HEC1-B cells were transfected with control or PEDF small interfering RNA (1.5 nM; 4392420; Ambion, Waltham, MA) using HiPerfect transfection reagent (Qiagen, Germantown, MD) for 24 hours. For all conditions, the cells were incubated in 1% FBS for 72 hours prior to measuring cell proliferation by the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (CellTiter96 Aqueous One Solution; Promega, Fitchburg, WI), which measures cell viability, as previously described (39) . Relative cell proliferation was expressed as percentage of untreated (i.e., vehicle-treated) controls at 100% and presented in the graph as means 6 SD. All treatments were performed in triplicate. To determine the effect of PEDF on cell cycle distribution in ECA cell lines, ECC-1 and HEC-1A cells were plated onto a 100-mm tissue culture dish at 6 3 10 5 cells/plate, grown to 60% to 70% confluence, synchronized in G 1 by serum starvation in 1% FBS for 24 hours, and subsequently treated with increasing concentrations of recombinant PEDF in 1% FBS for 48 hours for ECC-1 cells and 72 hours for HEC-1A cells. Propidium iodide staining, followed by fluorescence-activated cell sorting, was performed, as described (42) . The bar graphs show the percentage of cells in the phases of the cell cycle. The effect of PEDF on the levels of Caspase-3 and poly[ADP-ribose] polymerase (PARP) cleavage was determined on ECC-1 and HEC-1A cells. The cells, seeded in six-well plates at 1.0 3 10 5 cells/well for 48-hour time points and at 0.5 3 10 5 cells/ well for 72-hour time points, were cultured to 60% to 70% confluence, synchronized as above, and subsequently treated with recombinant PEDF for 48 and 72 hours, and cell lysates were analyzed by immunoblotting and densitometry.
In experiments in which primary EECs were treated with CM from ESFs or CAFs derived from different patients, ESFs were seeded at 5 3 10 5 in a T75 flask and cultured for 24 hours in 10% FBS. Subsequently, the cells were synchronized by incubation in serum-free media for 24 hours, and the CM was collected (13.0 ml) from the cells. FBS was added to the CM to a final concentration of 1% and then incubated with primary EECs from individual patients for 72 hours. Proliferation of primary EECs was determined by the MTS assay, and the values of CM treatment vs unconditioned media were compared. To determine whether ESFs and CAFs mediate Pg-induced inhibition of proliferation of EECs in cocultures in which soluble mediators would be released and exchanged from both the epithelial and stromal cells, ESFs or CAFs were plated on collagen type I-coated 24-well plates at 1.25 3 10 5 in 0.25 ml in DMEM-F12 in triplicates. Primary EECs were plated on growth factor-reduced Matrigel-precoated Millicell CM filter inserts (0.4 mm; Millipore) at 1.25 3 10 6 and placed upright into the well containing the stromal cells (not in contact) in McCoy media. E2 (100 nM) and Pg (100 nM) were incubated with the cells in serum-free media for 4 days. To determine proliferation by thymidine incorporation, the cells were incubated further for 2 hours with 0.04 ml [ 3 H]-thymidine (0.1 mCi/mL in PBS; PerkinElmer Life Sciences, Waltham, MA; NET027005MC). The cells were fixed with 10% trichloracetic acid for 15 minutes, followed by two washes with 10% trichloracetic acid; the DNA precipitate was dissolved in 0.3 ml 0.2 N NaOH; and the samples (0.1 ml) were counted in a Beckman scintillation counter (Beckman Coulter, Indianapolis, IN; LS6500). Monolayers of EECs (without stromal cells) served as a control. The graph shows growth as percentage of control at 100% for each treatment parameter.
Immunoblotting for PEDF, Caspase-3, PARP, p27, and Cks1
Following cell treatments described in individual experiments, whole-cell extracts were prepared in radioimmunoprecipitation assay buffer (150 mM NaCl, 50 mM Tris-HCl, 0.25% sodium deoxycholate, 1.0 mM Na 3 VO 4 , 1.0 mM EDTA, 1% Nonidet P-40), and nuclear and cytoplasmic fractions were prepared using the NE-PER kit (Thermo Scientific), as previously described (39) . Protein concentrations of the lysates and cellular fractions were quantified using the bicinchoninic acid protein assay kit (Thermo Scientific), and 20 mg/well protein was applied to a 10% acrylamide sodium dodecyl sulfate-polyacrylamide gel electrophoresis; 10 mg and 5 mg protein/well were used for cytoplasmic and nuclear fractions, respectively, as described (42) . The membranes were blocked for 1 hour with 5% nonfat dry milk prepared in Tris-buffered saline containing 0.1% Tween 20 (TBST; BP337; Fisher Scientific), followed by incubation with primary antibodies prepared in TBST at 4°C overnight. The primary antibodies used were rabbit anti-human PEDF (1:5000, AB-PEDF1; BioProducts MD), rabbit anti-Caspase-3 (1:500, 9665; Cell Signaling, Danvers, MA), rabbit anti-PARP (1:1000, 9542; Cell Signaling), mouse anti-human p27 kip1 (1:1000; clone 57, 610242; BD Biosciences, San Jose, CA), and rabbit anti-human Cks1 (1:500; to Cks1 C terminus; 36-6800; Invitrogen), as described (43) . To ensure equal loading, the blots were stripped and reprobed with mouse anti-human b-actin (1:10,000; A5441; Sigma-Aldrich). For purity of cytoplasmic and nuclear fractions, the blots were reprobed with mouse anti-a-tubulin (1:10,000, T5168; Sigma-Aldrich) and rabbit anti-sp1 (1:1000, Sc-14027; Santa Cruz Biotechnology, Dallas, TX), respectively. The membranes were incubated with the secondary antibodies consisting of either peroxidase-conjugated goat anti-mouse (1:2000; 32430; Thermo Scientific) or goat antirabbit immunoglobulin G (1:2500; 32460; Thermo Scientific) prepared in TBST at room temperature for 1 hour. Protein bands were detected using SuperSignal West Dura Extended Duration Substrate kit (34075; Thermo Scientific), followed by exposure to x-ray film (HyBlot; Denville Scientific, Holliston, MA; E3012). The blots were subjected to densitometric scanning using an EDAS 290 and Kodak Logic-100 ID Image Analysis Software, and the protein bands were quantified by normalizing each band to b-actin in the same well. The values were expressed as fold increase or percentage decrease by comparison with the untreated control. The relative intensity of each band is shown below each well on the blot.
Gene transcription by quantitative reverse transcription PCR
ECC-1 cells seeded at 2.0 3 10 5 in a six-well plate and stromal cells seeded at 5 3 10 5 in a T75 flask were cultured for 24 hours in 10% FBS and synchronized in serum-free medium for 24 hours. Total RNA was isolated using the RNeasy Mini kit (Qiagen; 74104). First-strand complementary DNA was synthesized using the iScript kit (Bio-Rad, Hercules, CA; 1708841). Quantitative reverse transcription PCR was performed using the iTaq Universal SYBR Green Supermix (Bio-Rad; 172-5121) in a CFX96 Touch quantitative PCR system (Bio-Rad) using the SERPINF1 (PEDF) and GAPDH primers listed in Table 1 . Amplifications were carried out with an initial denaturation at 95°C for 3 minutes, followed by 40 cycles of 95°C for 10 seconds and 60°C for 30 seconds. A melting curve was conducted to ensure primer specificity. SERPINF1 expression relative to GAPDH was calculated using the DDC T method.
Quantitation of PEDF in CM by enzyme-linked immunosorbent assay
To determine the concentration of PEDF protein in CM collected from ECC-1 cells, cells were seeded at 0.6 3 10 5 cells/ well in 24-well tissue culture plates, cultured to 60% to 70% confluence, and the cells were synchronized in serum-free media for 24 hours. Cells were washed with PBS and treated in triplicate with E2 (1 nM), E2 (100 nM) plus MPA (100 nM), E2 (1 nM) plus ICI (10 nM), E2 (100 nM) plus MPA (100 nM) plus RU486 (10 mM), ICI (10 nM), and RU486 (10 mM) in serumfree media without phenol red. After 48 hours, the supernatants were collected, centrifuged for 10 minutes at 5000 rpm, and subjected to enzyme-linked immunosorbent assay (ELISA) using the PEDF ChemiKine kit (Millipore, CYT420), according to manufacturer's instructions. Levels of PEDF were normalized to the total protein concentration in each well determined by bicinchoninic acid and expressed as pg/mg. The concentrations of PEDF protein in CM from ESFs and CAFs in response to hormones were performed by seeding ESFs and CAFs at 10 5 cells/well in six-well plates, and, after 24 hours, the cells were washed with PBS and treated with E2 (1 nM) or E2 (100 nM) plus MPA (100 nM) in serum-free RPMI 1640 medium without phenol red. After 48-hour incubation, the supernatants were collected, centrifuged for 15 minutes at 6000 rpm, and stored at 280°C. PEDF levels in the CM media were quantified using the PEDF chemiKine kit (Millipore).
Table 1. List of Primers
Primer Sequence
E2 and Pg induction of PEDF promoter activity
The promoter regions of the PEDF gene from positions 2844 to +97 and 21642 to +107 were amplified by PCR using genomic DNA isolated from ECC-1 cells and the DNA cloned into the luciferase reporter vector pGL3-Basic (Promega) using the MluI/ BglII restriction sites. The primer sequences are listed in Table 1 . The DNA inserts were verified by oligonucleotide sequencing at New York University Langone Medical Center Core (Genewiz, Cambridge, MA). To determine whether E2 or Pg induces PEDF promoter activity, ECC-1 cells were seeded at 3 3 10 5 cells/well in 12-well plates, and, after 24 hours, the cells were cotransfected with 0.5 mg reporter construct and 0.5 mg pRL-SV40 (Promega), a plasmid that encodes Renilla luciferase, as an internal control, using Lipofectamine 2000 (Invitrogen). Cells were serum starved in 1% charcoal-stripped FBS for 24 hours, followed by treatment with 1 nM E2 or 100 nM E2 plus 100 nM MPA (in triplicates or quadruplicates) for 18 hours, and cell lysates were collected in 30 ml reporter lysis buffer (Promega); the lysates were stored at 220°C until use. Firefly and Renilla luciferase activities were measured (Berthold-LUMAT LB 9507) separately using the luciferase assay and Renilla luciferase assay systems (Promega), according to manufacturer's instructions. Relative promoter activities were calculated as the ratio of firefly/Renilla luciferase units that were normalized to untreated controls.
Statistical analysis
All statistical analyses were carried out using GraphPad Prism software and presented as means 6 SD or standard error of the mean. For MVD and PCNA assessment in the mouse PEDF-null and wild-type tissues, positive cells were averaged and statistical significance was calculated by Student t test. For the proliferation assay and PEDF promoter activity, the statistical significances between groups were determined using the Student t test or one-way analysis of variance, followed by Dunn test for multiple comparisons in the PEDF ELISA in ECC-1. For the stromal cell PEDF ELISA, statistical significance between groups was determined using two-way analysis of variance, followed by Dunn test. Correlation between PEDF-secreted levels and proliferation was measured by the Pearson product moment correlation.
Results
The endometrium of PEDF-null mice demonstrates glandular hyperplasia and a high rate of proliferation Similar to human endometrial atypical CH (AEH), PEDF-null mice demonstrate multilayered endometrial epithelial glandular cells with numerous mitoses (arrows; Fig. 1 (Ab)] compared with their genetically wild-type mouse strain showing the normal one layer of epithelial cells composing the glands [ Fig. 1(Aa) ]. This finding implicated PEDF in the regulation of endometrial proliferation. In the human endometrium, E2-induced hyperplasia is often the precursor to type I endometrioid adenocarcinoma, as evidenced by concurrent AEH and ECA (34) . As depicted in Fig. 1 (Ac) and 1(Ad), by PCNA immunostaining the PEDFnull glandular epithelial cells show a 73% increase in the number of mitotic cells [arrows; P # 0.001; Fig. 1(B) ] compared with the wild-type mouse. Supplemental Fig. 2 illustrates an area of hyperplasia in the PEDF-null mouse uterus with glandular epithelial cells immunostained for PCNA (black arrows), as a match for the hematoxylin and eosin section shown in Fig. 1(Ab) . Figure 1 (Af) confirms the major well-known antiangiogenic function of PEDF as the PEDF-deficient mouse uterus shows a 60% increase in MVD compared with the wild-type control, as assayed by CD31 immunostaining [P # 0.001; Fig. 1(C) ]. These findings prompted the hypothesis that PEDF might normally inhibit endometrial cell proliferation and thus might play a significant role in the pathogenesis of ECA.
Exogenous PEDF inhibits proliferation of ECA cell lines and primary endometrial carcinoma cells and does not induce apoptosis
In addition to being a potent antiangiogenic protein, PEDF has been shown to inhibit proliferation of a variety of cancer cells in vitro, including colorectal, prostate, and gliomas (14, 16) . To determine whether PEDF inhibited proliferation of ECA cells, four different ECA cell lines and primary ECAs from four patient hysterectomies were synchronized and then treated with increasing concentrations of recombinant PEDF for 72 hours. As shown in Fig. 2(A) , PEDF dose dependently inhibited proliferation of HEC-1B, KLE, and RL-95-2 cell lines, by 42%, 38%, and 13%, respectively, within a range from 1 to 4 nM after 72-hour treatment. Higher concentrations of PEDF did not induce a greater effect for any of the cell lines and primary cells (data not shown). The ECC-1 cell line showed a greater growth-inhibitory response of 40% after 48-hour treatment with PEDF rather than 72 hours [Supplemental Fig. 3(A) ]. As illustrated by the linear graph in Fig. 2(B) , whereas cells from one primary papillary serous ECA (patient 2) were not growth inhibited by PEDF, primary ECA cells from three different patients representing different grades of type I endometrioid ECA yielded statistically significant responses of 13% [ECA grade I (patient 3); P , 0.05], 19% [ECA I (patient 4); P , 0.0001], and 12% [ECA grade III (patient 1); P , 0.01], with a peak concentration of 1 to 10 nM. Therefore, albeit a lower magnitude of response to PEDF was obtained for primary ECA cells compared with the ECA cell lines, exogenous PEDF inhibits proliferation of primary type I ECA cells. A trend of inhibition of proliferation was shown following treatment of primary EECs with PEDF; statistical significance might not have been achieved due to small sample number (SE = 2; PE = 5; data not shown). The effect of PEDF on cell viability related to cell number, as determined by the MTS assay (i.e., metabolic index), is not due to apoptosis as treatment of ECC-1, and HEC-1A cells did not show cell death represented by Caspase-3 or PARP cleavage by immunoblot analysis [ Fig. 2(C) ; Supplemental Fig. 3(B) ]. Cell cycle analysis by propidium iodide staining and fluorescence-activated cell sorter shows that PEDF treatment of ECA cells elicited a combined increase in G 1 and G 2 phases by ;10% and a concomitant 10% decrease in S phase with peak responses at 4 nM and 20 nM PEDF in ECC-1 [ Fig. 2(D) ] and HEC-1A [Supplemental Fig. 3(C) ]. These results indicate that the decrease in cell number following treatment with PEDF is due to blocking cells in G 1 and G 2 of the cell cycle and not by apoptosis. . (E) PEDF inhibits growth by an autocrine mechanism. HEC-1B cells were synchronized and treated with three different neutralizing anti-human PEDF for 72 hours, and cell viability was determined by comparing the untreated control and human nonimmune immunoglobulin G, using the MTS assay. A representative experiment is shown (n = 2). Data are expressed as mean 6 SD. (F) PEDF was genetically silenced in HEC1B cells by small interfering RNA transfection, and cell lysates were immunoblotted for PEDF and b-actin as a loading control. The bands were densitometrically scanned to determine knockdown efficiency. Knocking down PEDF increases cell number (proliferation). (G) HEC1B cells transfected with scrambled control small interfering RNA or PEDF small interfering RNA were synchronized, and cell proliferation was determined after 72 hours by the MTS assay. Percentage of growth was determined compared with the untreated control at 100% (n = 2). The statistical difference between treated and untreated cells in all of the above was determined by the Student t test. Graphs show the mean 6 SD; *P # 0.05; **P # 0.01; ***P # 0.001; ****P # 0.0001. into culture media [ Fig. 3(C) (untreated) ]. As ECA cells both respond to and produce PEDF, we determined whether inhibition of proliferation induced by PEDF is autocrine regulated, by incubating synchronized HEC1-B cells with PEDF antibodies from three different sources for 72 hours. As shown by the graph in Fig. 2(E) , these antibodies promoted a statistically significant increase in cell proliferation (13% to 51%; P # 0.01 to P # 0.0001) over the untreated control. In addition, following transient knockdown of PEDF in HEC-1B cells with PEDF small interfering RNA [61% efficiency; Fig. 2(F) ], a 25% statistically significant increase in proliferation was observed [P # 0.0152; Fig. 2(G) ]. Taken together, these data suggest that, at least in this ECA cell line, PEDF inhibits cell proliferation by an autocrine mechanism.
E2 and Pg regulate PEDF expression in ECA cell lines and primary ECA cells E2 induces proliferation of normal EECs in the proliferative (follicular) phase (PE) of the menstrual cycle, and, conversely, Pg blocks this estrogenic effect, causing cell differentiation in the SE phase. As type I ECA is linked to unopposed E2 mitogenic stimulation and PEDF inhibits ECA cell growth, we proposed that the pathogenesis of ECA might be due to an E2-induced decrease in PEDF, as exemplified by the endometrial hyperplasia observed in the PEDF-null mice [ Fig. 1(A), 1(B) ]. As shown in Fig. 3(A) , treatment of HEC-1A and HEC-1B ECA cell lines with E2 elicited a decrease in PEDF expression by 40%. To mimic the PR response to E2 in the SE of the menstrual cycle and to achieve a strong response to Pg, E2 (100 nM) is added together with Pg (100 nM) in all hormone treatments (39, 40, 44) . By contrast to the E2-induced decrease in PEDF, (E2 plus) Pg increases PEDF expression by 1.92-fold in HEC-1A and 1.15-fold in HEC-1B cells over the untreated control. Pg alone increases PEDF by 1.33-fold and 1.43-fold, respectively, in HEC-1A and HEC-1B cells. Both ICI 182,780 (ICI) and RU486 (RU), estrogen receptor (ER) and PR antagonists, respectively, quelled these hormone responses and reduced PEDF levels to near-basal levels, implicating the specificity of these hormone receptor-driven responses. PEDF has been shown to localize to the nucleus via a nuclear localization signal (45) . Nuclear-cytoplasmic fractionation was used to determine the subcellular localization of PEDF in response to E2 and E2 plus Pg. Following treatment with E2, there is a 40% decrease in cytoplasmic PEDF, and conversely, E2 plus Pg increased PEDF by 23% in the cytoplasmic fraction [ Fig. 3(B) ]. Nuclear levels of PEDF were unaffected by these hormones. Similar responses to hormones were reflected by the amount of PEDF released into media, as determined by ELISA [ Fig. 3(C) ]. Normalizing the amount of PEDF to cell protein levels to account for cell growth changes influenced by E2 and Pg, the CM from ECC-1 cells treated with E2 for 2 days contained 38% less PEDF (1.86 pg/mg in untreated vs 1.13 pg/mg; P # 0.005). Conversely, released PEDF increased by 57% in response to (E2 plus) Pg compared with E2 alone [1.97 pg/mg vs 1.13 pg/mg; P # 0.001; Fig. 3(C) ]. Because physiologically, Pg inhibits E2-induced mitogenesis in SE, the (E2 plus) Pg response is appropriately compared with E2 and not the untreated control. That PEDF levels were affected by E2 and (E2 plus) Pg via their respective hormone receptors, ER and PR, is demonstrated by blocking the hormone-induced changes in PEDF levels with the ER and PR inhibitors, ICI and RU486, respectively. As shown in Fig. 3(D) , the hormones affected normal EECs from PE in a similar manner to the ECA cell lines and E2 decreases PEDF by 41% and 69% in EEC lysates from patient 1 and patient 3, respectively. In contrast, (E2 plus) Pg did not increase PEDF in patient 3. (E2 plus) Pg specifically increased PEDF by 1.64-fold in EECs from patient 2, which was blocked by RU486, implicating that the response obtained is PR specific. The PEDF response to E2 and (E2 plus) Pg was varied in primary ECA cells. As shown in Fig. 3(E) , primary ECA cells from patient 1 (grade III) did not express PEDF, whereas ECA cells from patient 2 (papillary serous carcinoma) showed a relative abundance of basal PEDF expression [n.b., this patient did not respond to PEDF-induced inhibition of proliferation; Fig. 2(B) (gray line on graph) ]. However, neither patient's cells showed a change in PEDF levels in response to either hormone. In contrast, ECA cells from patient 3 (grade I) demonstrated basal levels of PEDF, responded to E2 by a 40% decrease in PEDF, and responded to Pg alone by 1.33-fold and to (E2 plus) Pg by an 8% decrease. Therefore, although small patient numbers were interrogated for PEDF responses to hormones, normal primary EECs appear to respond more consistently (3/3) compared with primary ECAs (1/3).
E2 and Pg regulate PEDF transcription
The data show that E2 and (E2 plus) Pg regulate PEDF protein levels in the ECA cell lines tested in this work, 3 of 3 primary EECs, and 1 of 3 primary ECAs (grade I; Fig. 3 ). As shown in Fig. 4(A) by real-time PCR, compared with 0 time, E2 reduced PEDF mRNA by 30% at 24 hours (P # 0.0001), whereas (E2 plus Pg) increased PEDF mRNA levels by 12 hours with a 1.5-fold increase at 24 hours (P # 0.005). It has been reported that the PEDF promoter harbors an E2 response element (ERE) and that E2 directly reduced PEDF promoter activity in ovarian surface epithelial cells (17) . In addition, putative Pg response elements (PREs) were predicted to be present in the PEDF promoter by a web search using the TRANSFAC database and a previously published gene sequence for PEDF (National Center for Biotechnology Information accession U29953). To determine whether E2 and Pg directly affect transcriptional activity of the PEDF promoter in the ECA cell line, ECC-1, luciferase reporter constructs were designed containing regions from 21642 to +107 (1.7 kb, PEDF P1) and from 2844 to +97 (0.9 kb, PEDF P2) of the PEDF gene, and each construct was transiently transfected into ECC-1 cells.
The putative ERE and PRE in these constructs are shown in Fig. 4(B) . The relative luciferase activity was measured following treatment with E2 and E2 plus Pg for 24 hours. As shown in Fig. 4(C) , using the 1.7-kb reporter construct (PEDF P1) containing both putative PREs and one ERE, PEDF promoter activity was reduced by ;30% in the presence of E2 (P , 0.05) and, conversely, was increased by 1.7-fold following Pg treatment (P , 0.001). However, using the 0.9-kb construct, PEDF P2, lacking the distal PRE, E2 similarly decreased transcriptional activity by 30% (P , 0.05), and Pg treatment increased transcriptional activity by 1.2-fold (not significant) over the vehicle control. This suggests that the distal PRE might be the major PRE site involved in Pg-induced PEDF transcription. The results using the larger construct, PEDF P1, containing both PRE and one ERE, are consistent with the data obtained by real-time reverse transcription PCR.
Endometrial stromal cells, but not CAFs, inhibit proliferation of EECs
The regulation of growth and development of hormone-regulated organs is contributed by epithelialstromal interactions and particularly soluble mediators emanating from stromal cells (35, 36, 38, 46) . This interaction becomes aberrant in cancer as carcinoma cells hijack CAFs to perpetuate malignant progression (47) (48) (49) . CAFs in the tumor microenvironment from malignant endometrium have been shown to stimulate proliferation of carcinoma cells in a variety of cancers, including ECA (49) (50) (51) (52) , by secreting growth factors and cytokines such as interleukin (IL)-1, IL-6, and IL-8 (52, 53) and the interaction between stromal cell-derived factor-1a secreted by CAFs and CXC chemokine receptor 4 on ECA cells (54) . To determine the role of CAFs compared with normal ESFs in the regulation of proliferation of EECs and ECA cells and, further, whether PEDF is secreted by the stroma to normally regulate epithelial proliferation in a paracrine manner, CM from ESFs isolated from normal endometrium of 10 patients and CAFs from five ECA tissues were collected and incubated with normal EECs from 10 different patients. Proliferation values were averaged and compared with untreated controls. As shown in Fig. 5(A) , CM from ESFs compared with CAFs inhibited proliferation by 19% (P # 0.001) and 9% (not significant), respectively. Therefore, these results suggest that ESF CM, but not CAFs, contain a secreted factor(s) that decreases proliferation of normal primary EECs. Consistent with inhibition of proliferation, these target EECs show an increase in the cyclin-dependent kinase inhibitor, p27 kip1 , and a decrease in Cks1, a protein that is associated with cellular proliferation [ Fig. 5(B) ].
Steroid regulation of epithelial growth and differentiation is mediated by steroid receptors on both epithelial and surrounding stroma (36, 37, 46) . Different from experiments using CM from ESFs and CAFs, exploiting cocultures of primary EECs incubated with ESFs or CAFs, soluble factors are released and exchanged by both cell populations that could affect the behavior and phenotype of these cells. To determine the effect of the presence of CAFs or ESFs on Pg-mediated inhibition of proliferation of EECs, CAFs or ESFs from eight patients, seeded onto tissue culture plates, were incubated in the presence of EECs on matrigel inserts in the same well, Pg was added, and inhibition of proliferation was assessed. As shown in Fig. 5(C) , the growth-inhibitory effect of Pg on EECs without stromal cells present is modest at 23% to 35%. However, in the presence of ESF, Pg induced 76% growth inhibition, and this effect was lost in the presence of CAFs, which stimulated EECs by 43%. These results suggest that ESFs enable a robust growth-inhibitory effect of Pg on EECs, but that CAFs have lost their ability to contribute to Pg-induced growth inhibition and, conversely, stimulate EEC growth. Moreover, we postulated that CAFs might express a decrease in PR owing to their inability to secrete soluble growth-inhibitory factors in response to Pg. Indeed, in Fig. 5(D) , we show by immunohistochemical analysis that PR expression is decreased in stroma(s) in CH compared with SE and nearly absent in stromal cells adjacent to the adenocarcinomatous glands (ECA grade II) compared with hyperplasia (P # 0.005), PE, and SE (P # 0.001), as reflected by the graph in Fig. 5(E) .
We show that PEDF regulates proliferation in an autocrine manner on ECA cells [ Fig. 2(E), 2(G) ]. To interrogate the possibility that inhibition of proliferation of EECs by ESFs might be due to paracrine PEDF, as shown in Fig. 5(A) , we measured the amount of PEDF in CM of ESFs and CAFs by ELISA. Notably, whereas a trend is shown and there was considerable variation among patients, there was no significant difference in the levels of secreted PEDF between ESFs and CAFs [ Fig. 5(F) ] nor in SERPINF1 (PEDF) gene expression between ESFs and CAFs [ Fig. 5(G) ]. In addition, the levels of PEDF from individual patients did not correlate with the growth-inhibitory activity of their CM on inhibition of proliferation of target EECs [ Fig. 5(H) ]. Whereas both CAFs and ESFs release PEDF, there was no growth-regulatory response to PEDF (data not shown). Classic experiments in mice have shown that ESFs express ER and PR and respond to E2 and Pg with subsequent release of soluble factors that exert growth-stimulatory and -inhibitory effects, respectively, on normal EECs (36, 37, 55) . Therefore, the effect of these hormones on the levels of PEDF secreted by ESFs was determined in the CM from 12 different patients and CAFs from 8 patients. As shown in Fig. 5(F) , similar to ECC-1 cells [ Fig. 3(C)] , E2 decreased the level of PEDF secreted by both ESFs and CAFs compared with the untreated control (P # 0.001). Physiologically, as Pg inhibits E2-induced proliferation in SE, we show that (E2 plus) Pg increase PEDF levels in both ESFs and CAFs when compared with E2 alone treatment [P # 0.05; Fig. 5(F) ]. These results indicate that PEDF secretion can be hormone regulated in cultured stromal cells derived from both normal and malignant tissues.
PEDF immunostaining of the normal and malignant human endometrium
Our results show that ECA cell lines and primary ECA cells in culture are inhibited by PEDF mainly in an autocrine manner with possible contribution of PEDF paracrine activity by ESFs, but not CAFs [ Fig. 5(A) ], and that PEDF is regulated by E2 and Pg. However, whether a decrease in PEDF plays a role in (E2-induced) endometrial carcinogenesis as shown in other cancers compared with normal tissue (14) (15) (16) 20) cannot be concluded from the in vitro data in this study. As endometrial hyperplasia resulted following knocking down PEDF in mice (Fig. 1) , we performed immunohistochemical analysis to determine whether PEDF expression in glandular epithelial cells is decreased in tissues from human endometrial hyperplasia, the precursor to ECA, and carcinoma compared with normal endometrial tissues from both phases of the menstrual cycle. As shown in Fig. 6 (Aa), and enlarged in Fig. 6 (Ab), weak punctate immunoreactivity is observed in the cytoplasm of the epithelium of SE (n = 6). In PE, the intensity of PEDF immunostaining was localized to the cytoplasm and ranged from weak to intense with an average higher intensity than SE [ Fig. 6(A) , compare Fig.  6 (Aa) and 6(Ab) with 6(Ac) and 6(Ad); PE; n = 6]. Stromal PEDF staining was moderate in PE, whereas SE was largely devoid of PEDF immunoreactivity. MPA (100 nM) for up to 24 hours. SERPINF1 (PEDF) gene expression normalized to GAPDH was calculated by quantitative reverse transcription PCR using the DDC T method. Fold change was calculated compared with 0-hour treatment. Statistical difference between 24-hour and 0-hour treatment was calculated by Student t test. Graph shows mean 6 SD; **P # 0.01; ****P # 0.0001; n = 3. (B) Diagram of PEDF gene luciferase reporter constructs. PEDF P1 contains entire PEDF promoter region replete with two PRE and one ERE. PEDF P2 lacks the distal PRE and thus contains one PRE and one ERE, as shown. (C) E2 decreases and Pg increases PEDF transcription; the distal PRE is required for maximal Pg-induced PEDF expression. ECC-1 cells were transfected with the reporter vectors PEDF P1 and PEDF P2, synchronized for 24 hours, and treated with E2 or E2 plus MPA for 18 hours. Luciferase activity was measured, as described in Materials and Methods. Graph shows mean 6 SD; *P # 0.05; ***P # 0.001; n = 3. doi: 10.1210/en.2017-00028 https://academic.oup.com/endo Figure 5 . ESFs, but not CAFs, inhibit proliferation of EECs. (A) CM from ESFs, but not CAFs, inhibit cell proliferation of EECs. CM from primary CAFs (n = 5) and ESFs (n = 10) were collected, as described in Materials and Methods, and added to primary EECs (n = 10) for 72 hours. Cell viability reflecting cell proliferation was assayed by the MTS assay. Proliferation values were averaged and compared with untreated controls. Graph shows mean 6 standard error of the mean; ***P # 0.001. (B) CM from ESFs increase p27 kip1 and decrease Cks1 in EECs. Total cell lysates collected from EECs treated with CM from primary CAFs or ESFs were subjected to immunoblotting to detect levels of p27 kip1 and Cks1. One representative blot (n = 2). (C) Pg decreases proliferation of EECs cocultured with ESFs, but increases proliferation of EECs cocultured with CAFs. Cocultures consisting of ESFs and EECs or CAFs and EECs were generated to determine the effect of the presence of CAFs or ESFs on Pg-mediated inhibition of proliferation of EECs. Monolayers of EECs without stromal cells served as a control (untreated). CAFs or ESFs were seeded onto collagen type I-coated tissue culture plates and then incubated in the presence of EECs seeded onto matrigel-coated inserts in the same well. The cocultures were treated with 100 nM E2 and 100 nM MPA (MPA/Pg; gray bars) or not treated (black bars) for 4 days, and inhibition of proliferation of EECs was assessed by 1) contributed by the number of nuclei staining per field in stroma (gray boxes) and glands (white boxes) in normal proliferative phase endometrium (PE; n = 9), SE (n = 5), hyperplasia (Hyper; n = 6), and ECA (n = 13 composed of grades I to III). Horizontal line shows median score; **P # 0.005; ***P # 0.001. (F) E2 decreases and Pg increases the amount of PEDF released into media by ESFs and CAFs. CAFs (n = 8) and ESFs (n = 12) were synchronized and treated with 1.0 nM E2 or (100 nM E2 plus) MPA for 48 hours, and secreted levels of PEDF (nM) were determined by ELISA. The graph shows the mean 6 standard error of the mean; *P , Variable immunostaining for PEDF in both the epithelial cell and stromal cell constituents of endometrial tissues from hyperplasia and different grades of type I endometrioid adenocarcinoma was observed. Figure  6 (Ba) demonstrates an average moderate cytoplasmic immunostaining for PEDF in the epithelium and stroma of SH (n = 5), which was similar in CH (data not shown; n = 4). A statistically nonsignificant decrease in PEDF immunostaining is observed in the glands of ECA, grades I and II [ Fig. 6 (Bb) and 6(Bc), respectively; ECA I, n = 11; ECA II, n = 5], which appeared largely cytoplasmic. Consistently, immunostaining was weak in the stroma of all grades of ECA. With increasing grades of ECA, both the normal glandular architecture is disrupted and the proliferating carcinoma cells displace the stromal component of the tissue. This is clearly observed in The graphs [ Fig. 6 (C) and 6(D)] display scatter plots of the scores from evaluation of PEDF intensity of immunostaining of individual patients. It is notable that, although the average intensity for each category of normal and malignant endometrium is shown in Fig. 6 (A) and 6(B), there was a wide range of patient variability of PEDF immunostaining for nearly all categories of patient tissues for both the epithelial and stromal cells of the endometrium; the epithelial cells show the greatest disparate expression of PEDF. In the epithelial compartment, no statistically significant difference was observed between the different groups. In the stromal compartment of SE tissues, PEDF intensity was significantly lower than in SH (P , 0.05), CH (P , 0.01), and ECA grade I (P , 0.05). Whereas it appears that the two grade III tissues have the weakest PEDF expression in both epithelial and stromal compartments, more tissue samples are necessary to confirm this conclusion. Taken together, PEDF, a putative inhibitor of cell proliferation, appears to be expressed independently of the proliferative status of human normal and malignant endometrium in vivo.
Discussion
As one of the most potent inhibitors of angiogenesis (13) and a plethora of other anti-cancer activities in .20 types of cancers to date (14, 20, 56) , the potential for PEDF as molecular target for cancer is well supported. Moreover, a role for PEDF in countering hormonal carcinogenesis related to endometrial, breast, and prostate cancers has been proposed (15, 23) . E2 has been shown to decrease PEDF concomitant with an increase in angiogenesis in the ovary and endometrium in cell culture and animal models (17, 31, 33) . Therefore, underscored by the inverse relationship between VEGF and PEDF via hormonal regulation by E2, PEDF is important in regulating angiogenesis in the endometrium as a function of the cyclical nature of the menstrual cycle. Whereas E2-related pathologies of the endometrium have been alleviated by PEDF in a rat model of endometriosis (32) and a mouse model of Tamoxifeninduced endometrial hyperplasia (33) , an antagonistic role of PEDF in E2-induced type I ECA has not been investigated. To this effort, our results in this work show that PEDF-null mice develop endometrial hyperplasia, a predisposition to human type I ECA. Moreover, in PEDF-null mice uterine tissue, the absence of PEDF is consequent to an increase in microvascular density and a higher rate of glandular epithelial proliferation. Accordingly, it has been reported that overexpression of PEDF in ECA cell lines reduces proliferation (57) . We show in the current study that exogenously added PEDF to cell cultures of ECA cell lines and primary carcinoma cells derived from type I ECA patient tissue inhibits cellular proliferation. Cell lines derived from adenocarcinomas showed greater sensitivity to PEDF than the adenosquamous carcinoma cell line, RL-95, and primary ECA cells from the highly aggressive serous papillary carcinoma were refractory to PEDF. The decrease in cell number was due to inhibition of cell proliferation and not apoptosis, as cleavage of PARP and Caspase-3, representing both the intrinsic (mitochondrial) and extrinsic (tumor necrosis factor-related apoptosisinducing ligand/FASL) cell death pathways, was not observed in ECC-1 cells. Furthermore, PEDF-induced inhibition of proliferation occurs by blocking cells in G 1 and G 2 phases of the cell cycle with a concomitant decrease in S phase in two ECA cell lines. Three different neutralizing antibodies to PEDF and transient PEDF knockdown significantly increased proliferation of HEC-1B cells, suggesting that PEDF inhibits proliferation in this cell line by an autocrine mechanism. Notably, PEDF has a signal peptide for secretion consistent with this autocrine effect and a bipartite nuclear localization signal (45, 58) ; PEDF has been shown to localize to the nucleus and bind to transcription factors involved in cell cycle regulation, such as ERa and Sp1 (59) . In contrast, PEDF reduced cell viability in a human normal ovarian surface epithelial cell line (OSE) and ovarian cancer cell lines, which was due to autocrine regulation of apoptosis (17) . Of the four known PEDF receptors, PEDFR, a plasma transmembrane-linked protein with phospholipase activity (60) , was shown to be expressed during the late secretory phase of the menstrual cycle (31) when PEDF levels are highest and, thus, PEDFR might mediate the growth-inhibitory function of PEDF. However, other potential PEDF receptors, intracellular signaling intermediates, and specific effects related to cell cycle in the context of growth inhibition warrant further investigation.
PEDF has been shown to be regulated by the ovarian steroid hormones E2 and Pg in a manner consistent with their effects on endometrial growth and angiogenesis in the mouse and human endometrium such that E2 decreases and Pg increases PEDF (31, 33) . We show in this study that E2 decreases PEDF protein levels by ;40% in both ECA cell lines (HEC-1A, HEC-1B) and normal primary EECs (69% decrease in one EEC). Pg (in the presence of E2 to increase PR and simulate the secretory phase of the menstrual cycle) induced a twofold increase in PEDF in HEC-1A cells and one EEC; one EEC was unresponsive. The higher PEDF response to Pg in the HEC-1B cell line without addition of E2 might be related to inherent PR density. The PEDF-related responses to E2 and Pg were blocked by receptor antagonists and, thus, were hormone receptor driven. Whereas grade I endometrioid-derived cells showed PEDF responsiveness to both hormones, primary ECA cells from papillary serous carcinoma and one grade III endometrioid tumor were unresponsive, possibly reflecting loss of ER and PR in these higher grade tumors (61) or patient heterogeneity (52) .
Consistent with the effects of hormones on PEDF intracellular protein levels, E2 decreases and Pg increases the level of PEDF secreted into culture media, measured by ELISA. Albeit the level of PEDF released is ostensibly lower than the minimum concentration that induces growth inhibition in vitro [0.015 nM (Pg-treated) vs 0.04 nM], the data suggest that PEDF induced by Pg has the potential to be autocrine growth inhibitory in the secretory phase of the menstrual cycle. Whereas the changes induced by E2 and Pg on the levels of PEDF protein are observed in the cytoplasm, as shown in HEC-1B cells, the hormone effects are shown to be genomic by directly affecting the PEDF promoter, as reflected by a decrease in PEDF transcription via the ERE and an increase in transcription by Pg via two PREs in a PEDF promoter construct. Pg binding via PR to two PREs caused a greater transcriptional response than the promoter construct containing only one PRE (2844 to +197; 1.7-fold compared with 1.20-fold), suggesting that the distal PRE may be the major PRE contributing to PEDF transcription. Changes in PEDF transcription levels might also be contributed by specific DNA-binding proteins together with the PR, and, certainly, nongenomic effects of these hormones have been shown (62, 63) .
Stromal cells surrounding epithelial glands play a significant role in the growth and differentiation of their adjacent epithelial cells, particularly in hormoneregulated tissues, as these mesenchymally derived cells express hormone receptors (35, 61, 64, 65) . Both cell:cell interactions as well as soluble mediators released by stroma in response to hormones strongly affect the epithelia (35) (36) (37) 66) . Moreover, whereas genetic events in the epithelial cells predispose to malignancy, the stromal cells surrounding carcinomatous glands (CAFs) are altered by their association with cancer cells and consequently secrete chemokines and other factors that promote malignant progression of the epithelial cells (46, 48, (52) (53) (54) (67) (68) (69) (70) . Similar to EEC and ECA (epithelial) responses to E2 and Pg, both ESFs and CAFs retain their ability to be responsive to these hormones, showing E2 downregulation and Pg upregulation, respectively, of the levels of PEDF. As aging predisposes to a higher rate of cancers, including ECA (67, 71) , PEDF was suggested as the factor in CM from ESFs derived from younger endometrium that inhibited the growth of ECA cell lines; ESFs from older patients lost this ability and, conversely, were growth stimulatory due to IL-1 secretion (72) . As the decline of PEDF expression levels in stroma with aging is thus implicated in endometrial carcinogenesis, we compared both PEDF expression levels in CAFs and ESFs and the effects of their respective CM on the proliferation of primary EECs from different patients. Our studies show that whereas both normal ESFs and CAFs have similar PEDF mRNA levels and secrete similar amounts of PEDF as measured by ELISA, only the CM from ESF significantly inhibited proliferation of normal primary EECs. Consistent with growth inhibition, the target EECs showed a concomitant increase in the cyclin-dependent kinase inhibitor, p27 kip1 , and an increase in Cks1, a multifunctional protein associated with cell cycle progression (73, 74) . However, we could not attribute paracrine inhibition of proliferation to PEDF because, on a patient by patient basis, inhibition of proliferation did not statistically correlate with the CM from ESFs containing higher potentially growth-inhibitory levels of PEDF.
As Pg inhibits primary EEC proliferation (39, 40) , we tested whether CAFs might be deficient in mediating this Pg-driven response on EECs grown in coculture in which soluble factors are exchanged by these cells. Interestingly, and consistent with the role of stromal cells in hormonedriven responses, whereas Pg decreased proliferation of EECs when cultured alone, the response was more than doubled in cocultures with normal ESFs, thereby suggesting soluble growth inhibitor(s) from stroma inhibited EEC proliferation. In contrast, cocultures of EECs with CAFs had the opposite effect, causing robust growth stimulation of these target cells. The lack of progesterogenic response might be due to decreased PR that we show in this study in vivo by IHC occurs in stroma surrounding hyperplastic and carcinomatous endometrial glands. This is supported by another study showing that both ERa and progesterone receptor A isoforms are decreased in CAFs compared with ESFs by IHC (61) . Therefore, both the decrease in stromal cell number with increasing grades of ECA and the absence of PR may contribute to the loss of paracrine growth regulation in endometrial hyperplasia and ECA, in which unopposed E2 (e.g., lack of Pg) is etiologically linked to this pathology. Whereas CAFs and ESFs apparently secrete a similar amount of PEDF in response to Pg and have the potential to inhibit growth through release of PEDF, in cocultures Pg-induced growth inhibition might be negated by the release of factors that stimulate growth of EECs. Studies show that CAFs promote progression of ECA through the secretion of IL-8, IL-6, monocyte chemoattractant protein-1, and VEGF, and stimulate growth via the stromal cell-derived factor-1a/CXC chemokine receptor 4 axis (52) (53) (54) 69) . Nevertheless, in comparison with other cancers, the stromal gene signature of ECA has been studied to a limited extent, and, therefore, additional experiments should provide better insight regarding the endometrial CAF secretome and its impact on cell proliferation. Notably, the concentration of PEDF determined by ELISA [0.05 nM in ESF and 0.04 nM in CAF CM; Fig. 5(F) ] is close to the minimum concentration required to induce a small growthinhibitory response [0.04 nM in ECA cell lines [ Fig.  2(D) ] and primary ECA cells from one patient [ECAI, 4; Fig. 2(B) ]. Because these in vitro experiments do not represent the in vivo levels of PEDF, it is possible that the amount of PEDF secreted by ESFs locally in vivo might be sufficient to inhibit proliferation of juxtaposed epithelial glands (EECs or ECAs). Thus, paracrine regulation of growth by PEDF released by ESFs is possible in the normal endometrium, in addition to autocrine growth regulation shown in this work in epithelial cells, and, importantly, as exemplified by ECA cell lines, these cancer cells appear to retain their ability to be autocrine growth regulated by PEDF and CAFs secrete a similar level of PEDF as ESFs. In vivo, the decrease in numbers of CAFs in (higher grade) ECA could account for loss of PEDF paracrine activity on carcinoma cells.
Increased expression of PEDF in many human cancers is associated with a better prognosis, and, conversely, reduced levels have been an indicator of poor prognosis in glioma, pancreatic adenocarcinoma, invasive melanoma, colorectal, nonsmall cell lung, prostate, ovarian cancers, and others (14, 17) . Our demonstration in this study of variable expression of PEDF protein in normal, hyperplastic, and ECA tissue was inconclusive for a role for PEDF in ECA development. Specifically, in the number of normal patients' tissues evaluated, we did not observe a significant difference in PEDF expression between human endometrial samples from proliferative and secretory phases. Although we did not have information on the day of the menstrual cycle when the SE tissue was derived, in another study, PEDF mRNA and protein expression was shown to be higher in late SE than before day 21 of the menstrual cycle (31) . Whereas in this work E2 decreases PEDF in primary EECs, ECA cell lines, ESFs, and CAFs, and PEDF inhibits cellular proliferation in primary ECA and ECA cell lines, one cannot conclude that PEDF has a growth-regulatory effect in vivo because PEDF, which should ostensibly be decreased in proliferating cells, was highly expressed in proliferative and hyperplastic endometrium as well as in grade I and II ECAs in some patients. This was unexpected because hyperplasia in the mouse endometrium was driven by loss of the PEDF gene, originally spurring the current studies. We previously reported that murine and human uterine cells respond differently to E2 stimulation (55) . In direct contrast to the murine endometrium, which depends entirely on the ER on stromal cells for an E2-induced response, using tissue recombinants of human and mouse epithelial and stromal cells, we showed that human uterine cells proliferate and upregulate PR independently of the presence of the activation function-1 domain of ERa in stromal cells. Therefore, this interspecies difference with respect to the response to E2 may be one explanation for the lack of association between loss of PEDF expression and human endometrial hyperplasia and grades I and II ECA. PEDF is considered as a therapeutic for E2-dependent pathologies, including cancer (15) , and appears in our study to play an important role in growth regulation of murine endometrium as well as in human endometrial cells in vitro. As it has been shown for another inhibitor of ECA proliferation, TGF-b, that is overexpressed in cancer (75), it is possible that deregulation of PEDF-R or PEDF downstream signaling might occur in ECA cells blocking negative feedback control of PEDF expression such that, antithetically, PEDF levels are high in proliferating cells.
